4 terminated. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 4 |
| Phase 2 | 2 | Terminated 2 |
Follow SCLC: new trials by email Literature Review of SCLC trials Research Report on SCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi), GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi), GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi) - SCLC, Malignant Melanoma | Phase 1 | Terminated | Y-mAbs Therapeutics | 23 | 2022-11-17 | 2026-06-18 |
| Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer Nivatrotamab - SCLC | Phase 1 / Phase 2 | Terminated | Y-mAbs Therapeutics | 3 | 2021-08-17 | 2023-08-14 |
| A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection MRX34 - Primary Liver Cancer, SCLC | Phase 1 | Terminated | Mirna Therapeutics, Inc. | 155 | 2013-04-01 | 2016-09-27 |
| A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy pemetrexed, cisplatin, radiation - Small Cell Lung Cancer, Carcinoma, Small Cell | Phase 1 / Phase 2 | Terminated | Eli Lilly and Company | 9 | 2007-02-01 | 2009-10-28 |
Melanoma (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Carcinoma, Small Cell (1) · Lymphoma (1) · Multiple Myeloma (1) · Sarcoma (1) · Small Cell Lung Carcinoma (1)
Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Carcinoma (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2) · Nevi and Melanomas (2) · Skin Diseases (2) · Skin Neoplasms (2) · Skin and Connective Tissue Diseases (2) · Adenocarcinoma (1) · Blood Protein Disorders (1)
Cisplatin (1) · Pemetrexed (1) · Radiation (1)
Y-mAbs Therapeutics (2) · Eli Lilly and Company (1) · Mirna Therapeutics, Inc. (1)
United States (3) · Belgium (1) · Netherlands (1) · South Korea (1)
O'Neill VIncent, MD (1) · Taofeek K Owonikoko, MD/PhD (1)